Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01217255
Other study ID # 1000020214
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 2010
Est. completion date October 2013

Study information

Verified date June 2018
Source The Hospital for Sick Children
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Because of high cost, persons with hemophilia in many developing countries cannot afford adequate treatment. For example, many persons with hemophilia in India and China are only rarely treated with factor replacement in response to bleeds, and as a result many have developed significant arthropathy and disability. A pilot study in China estimated the mean Hemophilia Joint Health Score (HJHS) at 13.1 (SD 9.03) suggesting that these children had highly prevalent, severe joint disease. The lack of relationship between the HJHS and treatment history suggests overall inadequate therapy.

The proposed study will quantify the burden of arthropathy, physical disability, and quality of life (QoL) in boys with hemophilia in Brazil - where comprehensive treatment is just beginning to be widely available. This study will also provide an opportunity to compare these outcomes to those observed in Canada, where the dominant therapy has become life-long prophylaxis.


Description:

In order to quantify the burden of illness in hemophilia, and to study the response to different treatments, it is necessary to have quantitative outcome measures of high validity and reliability. The International Prophylaxis Study Group (IPSG - chair Dr. Victor Blanchette) was established in 2001 with the stated purpose of developing and testing outcome tools for this purpose. The group has developed a magnetic resonance imaging (MRI) score for quantifying arthropathy (representing the domain of structure and function domain in the ICF framework), a quantitative physical examination score, and the Hemophilia Joint Health Score or HJHS, to replace the older and less sensitive World Federation of Hemophilia (WFH) score (representing the domain of structure and function in the ICF). In addition Canadian investigators have also developed a quality of life measure for boys with hemophilia, the Canadian Hemophilia Outcomes Kids' Life Assessment Tool or CHO-KLAT (representing the domain of participation in the ICF).

We will use these tools, and other validated measures, to begin to determine the burden of hemophilia in Brazil and compare it to the burden of disease in Canada. Additionally, we will use this study to demonstrate the validity of these tools in the Brazilian population.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date October 2013
Est. primary completion date October 2013
Accepts healthy volunteers No
Gender Male
Age group 7 Years to 18 Years
Eligibility Inclusion criteria

- Hemophilia A or B moderate or severe as determined by serum factor activity = 5%

- Age 7 - 18 yrs. inclusive

- At least one parent or guardian fluent in written Portuguese or English and able to complete the study outcome questionnaires.

Exclusion criteria

- None (Children with inhibitors will be allowed into the study for 2 reasons: i) our study aims to document the health of persons with hemophilia in a generalizable way, ii) not all children will have had inhibitor testing done.)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Brazil Universidade Estadual de Campinas, UNICAMP Campinas Sao Paulo
Brazil Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo Sao Paulo
Brazil Universidade Federal de São Paulo (UNIFESP) Sao Paulo
Canada The Hospital for Sick Children Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
The Hospital for Sick Children

Countries where clinical trial is conducted

Brazil,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Burden of Illness Burden of disability for Brazilian and Canadian children will be be determined by analysis of the following domains:
Structure and Function Domain (HJHS score, Biometrics,Radiographs) Activity Domain (ASK and FISH scales) Participation Domain (CHO-KLAT and PedsQL Quality of Life Questionnaire) Health Condition Domain (bleeding frequency) Personal Factors Domain (Ethnicity, level of education of parent/guardian, habitual exercise) Environmental Domain (Household income of parent/guardian)
3 years
Secondary The Activity Scale for Kids (ASK) Children's self-reported activities will be measured with the Activity Scales for Kids (ASK) as part of the Activity Domain Day 1
Secondary Functional Independence Scale for Hemophilia (FISH) Observed activity limitations will be measured with the FISH as part of the Activity Domain.
The FISH has been validated for use in developing countries. It consists of observed activities of daily living that are scored for quality.
Day 1
Secondary Hemophilia Joint Health Score (HJHS) The HJHS is a valid and reliable scored measure of joint structural limitations as applied to the index joints.
This score will be a measure of the Structure and function domain.
Day 1
Secondary Radiographs Radiographs will be taken of all 6 index joints. This will be done as part of the structure and function domain. Day 1
Secondary Canadian Haemophilia Outcomes - Kids Life Assessment Tool (CHO-KLAT) After the completion of the pre-study cultural validation of the Brazilian translation of the CHO-KLAT scale, we will use it as a Quality of Life tool to measure the Participation domain Day 1
Secondary Bleeding Frequency Families will be interviewed to determine bleeding frequency in the last 6 months. This factor will be incorporated into the Health condition domain. Day 1
Secondary Biometrics The height and weight will be compared to national nomograms. Days 1
Secondary Personal Factors Ethnicity, level of education of the parent-guardian will be self-reported. Day 1
Secondary Environmental domain Whether a subject lives in a rural or urban area and household income will be recorded. Day 1
See also
  Status Clinical Trial Phase
Completed NCT03834727 - Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders
Completed NCT03191799 - A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors Phase 3
Completed NCT01599819 - BAX 855 Dose-Escalation Safety Study Phase 1
Terminated NCT04541628 - Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A Phase 1/Phase 2
Completed NCT02847637 - A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors Phase 3
Completed NCT04072237 - Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia Phase 1
Completed NCT04085458 - Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation) Phase 4
Completed NCT04565236 - A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A Phase 4
Recruiting NCT05987449 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A Phase 1/Phase 2
Active, not recruiting NCT04621916 - Preventing Inhibitor Recurrence Indefinitely Phase 4
Not yet recruiting NCT02888223 - Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A Phase 1
Completed NCT02528968 - National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A N/A
Completed NCT02225483 - Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function N/A
Completed NCT02199717 - An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia N/A
Terminated NCT00995046 - Individually Tailored Prophylaxis in Patients With Severe Hemophilia A N/A
Completed NCT00969319 - Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America N/A
Completed NCT00868530 - Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects Phase 3
Completed NCT00839202 - Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay N/A
Completed NCT00629837 - Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980 Phase 1
Completed NCT02093741 - ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)